What’s Going on with Solid Biosciences?
Solid Biosciences (SLDB) will be presenting 1.5-year data, plus patient-reported outcomes, for the company’s ongoing SGT-001 Duchenne muscular dystrophy (DMD) IGNITE DMD Phase I/II clinical trial.
Duchenne muscular dystrophy is a rare genetic disorder defined by progressive muscle degeneration and loss of muscle caused by alterations in the dystrophin protein. Pre-market today, SLDB shares were trading at $3.05, which is a 1.67% increase in price.
What Does This Mean for SLDB?
The IGNITE DMD study’s clinical investigator, Vamshi Rao, MD, will present the data today (Sept. 23) at the World Muscle Society 2021 Virtual Congress. “The data presented today demonstrate durable expression and function of microdystrophin protein in biopsy samples collected 12 to 24 months post-dosing of SGT-001,” Dr. Rao explained. “Additionally, these data provide encouraging evidence of functional benefit at 1.5 years post-treatment compared with natural history data and show meaningful improvement in patient-reported outcomes.”
Solid Biosciences believe SGT-001 has “the potential to provide differentiated benefit to patients with Duchenne," according to CEO Ilan Ganot. The company has plans to dose additional patients in the ongoing IGNITE DMD trial as well.
SLDB has a Fundamental Rank of 97. Find out what this means to you and get the rest of the rankings on SLDB!
Solid Biosciences Inc is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
